98 related articles for article (PubMed ID: 24286413)
1. Analysis of Graves' ophthalmopathy patients' tear protein spectrum.
Jiang LH; Wei RL
Chin Med J (Engl); 2013 Dec; 126(23):4493-8. PubMed ID: 24286413
[TBL] [Abstract][Full Text] [Related]
2. Altered tear composition in smokers and patients with graves ophthalmopathy.
Baker GR; Morton M; Rajapaska RS; Bullock M; Gullu S; Mazzi B; Ludgate M
Arch Ophthalmol; 2006 Oct; 124(10):1451-6. PubMed ID: 17030713
[TBL] [Abstract][Full Text] [Related]
3. Graves' orbitopathy results in profound changes in tear composition: a study of plasminogen activator inhibitor-1 and seven cytokines.
Ujhelyi B; Gogolak P; Erdei A; Nagy V; Balazs E; Rajnavolgyi E; Berta A; Nagy EV
Thyroid; 2012 Apr; 22(4):407-14. PubMed ID: 22385289
[TBL] [Abstract][Full Text] [Related]
4. Establishment of a tear protein biomarker panel differentiating between Graves' disease with or without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
PLoS One; 2017; 12(4):e0175274. PubMed ID: 28419103
[TBL] [Abstract][Full Text] [Related]
5. The potential of tear proteomics for diagnosis and management of orbital inflammatory disorders including Graves' ophthalmopathy.
Khazaei H; Khazaei D; Verma R; Ng J; Wilmarth PA; David LL; Rosenbaum JT
Exp Eye Res; 2021 Dec; 213():108813. PubMed ID: 34742692
[TBL] [Abstract][Full Text] [Related]
6. Comparative proteomic analysis of tear fluid in Graves' disease with and without orbitopathy.
Aass C; Norheim I; Eriksen EF; Børnick EC; Thorsby PM; Pepaj M
Clin Endocrinol (Oxf); 2016 Nov; 85(5):805-812. PubMed ID: 27256639
[TBL] [Abstract][Full Text] [Related]
7. Identification of tear fluid biomarkers in dry eye syndrome using iTRAQ quantitative proteomics.
Zhou L; Beuerman RW; Chan CM; Zhao SZ; Li XR; Yang H; Tong L; Liu S; Stern ME; Tan D
J Proteome Res; 2009 Nov; 8(11):4889-905. PubMed ID: 19705875
[TBL] [Abstract][Full Text] [Related]
8. Tear proteomic analysis of patients with type 2 diabetes and dry eye syndrome by two-dimensional nano-liquid chromatography coupled with tandem mass spectrometry.
Li B; Sheng M; Xie L; Liu F; Yan G; Wang W; Lin A; Zhao F; Chen Y
Invest Ophthalmol Vis Sci; 2014 Jan; 55(1):177-86. PubMed ID: 24282230
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress markers in tears of patients with Graves' orbitopathy and their correlation with clinical activity score.
Choi W; Li Y; Ji YS; Yoon KC
BMC Ophthalmol; 2018 Nov; 18(1):303. PubMed ID: 30463536
[TBL] [Abstract][Full Text] [Related]
10. Tear lipocalin is the predominant phosphoprotein in human tear fluid.
Zhao Z; Liu J; Wasinger VC; Malouf T; Nguyen-Khuong T; Walsh B; Willcox MD
Exp Eye Res; 2010 Feb; 90(2):344-9. PubMed ID: 19951704
[TBL] [Abstract][Full Text] [Related]
11. Proteomics Screening of Differentially Expressed Cytokines in Tears of Patients with Graves' Ophthalmopathy.
Song RH; Wang B; Yao QM; Li Q; Jia X; Zhang JA
Endocr Metab Immune Disord Drug Targets; 2020; 20(1):87-95. PubMed ID: 31237218
[TBL] [Abstract][Full Text] [Related]
12. Thyroid-associated orbitopathy and tears: A proteomics study.
Kishazi E; Dor M; Eperon S; Oberic A; Hamedani M; Turck N
J Proteomics; 2018 Jan; 170():110-116. PubMed ID: 28887209
[TBL] [Abstract][Full Text] [Related]
13. Elevation of human alpha-defensins and S100 calcium-binding proteins A8 and A9 in tear fluid of patients with pterygium.
Zhou L; Beuerman RW; Ang LP; Chan CM; Li SF; Chew FT; Tan DT
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2077-86. PubMed ID: 19168894
[TBL] [Abstract][Full Text] [Related]
14. Diurnal tear cycle: evidence for a nocturnal inflammatory constitutive tear fluid.
Sack RA; Tan KO; Tan A
Invest Ophthalmol Vis Sci; 1992 Mar; 33(3):626-40. PubMed ID: 1544788
[TBL] [Abstract][Full Text] [Related]
15. Proteomics Differentiate Between Thyroid-Associated Orbitopathy and Dry Eye Syndrome.
Matheis N; Grus FH; Breitenfeld M; Knych I; Funke S; Pitz S; Ponto KA; Pfeiffer N; Kahaly GJ
Invest Ophthalmol Vis Sci; 2015 Apr; 56(4):2649-56. PubMed ID: 25829418
[TBL] [Abstract][Full Text] [Related]
16. Tear-derived exosomal biomarkers of Graves' ophthalmopathy.
Shi TT; Zhao RX; Xin Z; Hou ZJ; Wang H; Xie RR; Li DM; Yang JK
Front Immunol; 2022; 13():1088606. PubMed ID: 36561758
[TBL] [Abstract][Full Text] [Related]
17. Characterization of human tear proteome reveals differentially abundance proteins in thyroid-associated ophthalmopathy.
Zhou X; Wei R; Wang R
PeerJ; 2022; 10():e13701. PubMed ID: 35846879
[TBL] [Abstract][Full Text] [Related]
18. Proteomics in autoimmune thyroid eye disease.
Okrojek R; Grus FH; Matheis N; Kahaly GJ
Horm Metab Res; 2009 Jun; 41(6):465-70. PubMed ID: 19373747
[TBL] [Abstract][Full Text] [Related]
19. Corneal involvement in Graves' orbitopathy: an in vivo confocal study.
Villani E; Viola F; Sala R; Salvi M; Mapelli C; Currò N; Vannucchi G; Beck-Peccoz P; Ratiglia R
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4574-8. PubMed ID: 20435595
[TBL] [Abstract][Full Text] [Related]
20. The tear cytokine profile in patients with active Graves' orbitopathy.
Yang M; Chung Y; Lang S; Yawata N; Seah LL; Looi A
Endocrine; 2018 Feb; 59(2):402-409. PubMed ID: 29147850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
